|
- IRMS - Nicolae Testemitanu SUMPh
- REVISTE MEDICALE NEINSTITUȚIONALE
- One Health & Risk Management
- One Health & Risk Management 2021
- One Health & Risk Management Vol. 2 No 4, 2021 Supplement
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/18288
Title: | Laboratory diagnosis approaches of COVID-19 infection |
Authors: | Hujeirat, Ibrahim Ahmad |
Keywords: | coronavirus disease;laboratory diagnosis of COVID-19;SARS-CoV2 |
Issue Date: | 2021 |
Publisher: | Asociația de Biosiguranță și Biosecuritate din Republica Moldova |
Citation: | HUJEIRAT, Ibrahim Ahmad. Laboratory diagnosis approaches of COVID-19 infection. In: One Health & Risk Management. 2021, vol. 2(suppl.), no. 4, p. 76. ISSN 2587-3466. |
Abstract: | Introduction. The coronavirus disease 2019 (COVID-19), is a global pandemic caused by
the severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic has forced
the scientific community to rapidly develop highly reliable diagnostic methods in order to
effectively and accurately diagnose this pathology, thus limiting the spread of infection. A
robust and responsive testing infrastructure is essential to our success in stopping the
spread of SARS-CoV-2, the virus that causes COVID-19. At present, nucleic acid amplification methods represent the gold standard for the diagnosis of COVID-19 infection and together with clinical and radiological investigations, have improved the ability to correctly
and rapidly diagnose a COVID-19 infection.
Material and methods. This paper analysis the major aspects of this topic published and
were based on 65 bibliographic sources of authors across the country and abroad using
Academic Google and PubMed databases. (France, USA, Germany, Italy, Norway, Canada,
Romania, Republic of Moldova etc).
Results. Entire world have faced the second wave of COVID-19 pandemic which was characterized by an increased number of infections and related deaths worldwide. Timely and
accurate COVID-19 testing is an essential part of the management of the COVID-19 crisis.
The study showed that the persons with signs or symptoms of COVID-19 should have diagnostic testing. The handling of samples must comply with the requirements of biosafety
and biosecurity. All clinical specimens may contain potentially infectious materials. Precautions should be taken when handling specimens suspected or confirmed to be positive
for SARS-CoV-2. Suspected and confirmed SARS-CoV-2 positive clinical specimens, cultures, or isolates should be packed and shipped as UN 3373 Biological Substance, Category
B and handled in a Biosafety Level 3 laboratory using BSL-3 practices.
In the preanalytical stage, collecting the proper respiratory tract specimen at the right
time from the right anatomic site is essential for a prompt, accurate molecular diagnosis
of COVID-19. The tests used for COVID-19 can be classified into two groups. The first group
contains tests that can detect the presence of the virus itself - RNA and antigen tests. The
second group of tests detects the immune response of the body against the SARS-CoV-2
virus, i.e. they report on past or ongoing infection with the virus - antibody tests. The selection and interpretation of SARS-CoV-2 tests should be based on the context in which
they are being used, including the prevalence of SARS-CoV-2 in the population being
tested.
Conclusions. The ongoing, outbreak of COVID-19 globally has emphasized the importance
of the laboratory diagnosis of human coronavirus infections in order to limit the spread as
well as to appropriately treat patients who have a serious infection. In diagnosis of COVID19 is recommend to take into account, the test to be used, the patient's medical history,
the time of the suspicious SARS-CoV-2 exposure, the type of sample analyzed and interpretation of the result. |
metadata.dc.relation.ispartof: | One Health & Risk Management: The National Scientific Conference with international participation ”ONE HEALTH” approach in a changing world |
URI: | https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/issue/view/17/18 http://repository.usmf.md/handle/20.500.12710/18288 |
ISSN: | 2587-3458 2587-3466 |
Appears in Collections: | One Health & Risk Management Vol. 2 No 4, 2021 Supplement
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|